South & Central America Organoids Services Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The organoids services market in South and Central America is projected to grow significantly, reaching an estimated US$ 806.23 million by 2031, up from US$ 194.86 million in 2024. This growth represents a compound annual growth rate (CAGR) of 22.5% from 2024 to 2031.

Executive Summary and Market Analysis

The market is divided into three main regions: Brazil, Argentina, and the Rest of South and Central America. The anticipated growth in this market is driven by several factors, including a rising incidence of cancer, increased government initiatives, and heightened research and development activities focused on organoids.

Market Segmentation Analysis

The South and Central America organoids services market can be segmented by type, application, and source:

1. By Type: The market includes various organoid types such as intestine, liver, stomach, pancreas, lung, brain, kidney, and others. In 2024, the intestine segment is expected to dominate the market share.

2. By Application: The applications of organoids are categorized into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, among others. The developmental biology disease segment is projected to hold the largest market share in 2024.

3. By Source: The market is divided into two sources: pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment is anticipated to have a larger market share in 2024.

Market Outlook

The advancement of the healthcare sector globally has led to an increased demand for organoids, which in turn drives innovation and development in the market. This includes new product launches, partnerships, and acquisitions. Notable recent developments include:

• June 2024: Molecular Devices, LLC opened a new facility in Cardiff, UK, designed for the large-scale production of patient-derived organoids (PDOs) using innovative bioprocess technology.
• May 2024: InSphero entered a partnership with Genome Biologics to commercialize a 3D Cardiac Organoid Platform, enhancing heart disease research capabilities.
• January 2024: HUB Organoids launched IntegriGut Screen services, utilizing IBD patient-derived organoid monolayers to support the development of new therapies for inflammatory bowel disease (IBD).
• July 2023: Molecular Devices expanded its custom organoid line service to cater to high-throughput applications.
• February 2023: A strategic collaboration was announced between Molecular Devices and HUB Organoids to advance 3D biology technologies.
• December 2022: Molecular Devices acquired Cellesce Ltd. to enhance the production of PDOs for drug screening.
• August 2021: STEMCELL Technologies partnered with HUB to provide tissue-derived organoids for preclinical testing.
• May 2020: CELLINK collaborated with AstraZeneca to develop 3D bioprinted liver organoids for drug discovery.
• February 2020: InnoSer and Organotherapeutics announced a collaboration to commercialize midbrain organoids for Parkinson's disease research.

These developments indicate a robust growth trajectory for the organoid services market, driven by strategic collaborations and technological advancements.

Country Insights

The market is primarily composed of Brazil, Argentina, and the Rest of South and Central America, with Brazil holding the largest market share in 2024. The growth in Brazil can be attributed to increased investments in biotechnology and life sciences, supported by government initiatives and private funding aimed at enhancing research capabilities. The rising prevalence of chronic diseases necessitates more effective drug development and personalized medicine solutions, which organoids can provide by mimicking human organ functions for disease modeling and drug testing. Additionally, collaborations between academic institutions and industry players are fostering the adoption of organoid technologies, translating research into practical applications. The focus on improving healthcare outcomes and the demand for reliable preclinical models are further driving pharmaceutical companies to integrate organoids into their drug discovery processes, benefiting the organoid services market in Brazil.

Company Profiles

Key players in the South and Central America organoids services market include CUSABIO TECHNOLOGY LLC, Cyprio, Eurofins Scientific SE, HUB Organoids B.V., InnoSer, InSphero, LABTOO, Molecular Devices, LLC, Oncodesign Services, and Sino Biological Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions to their customers.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America organoids services market.
• Highlights key business priorities to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the South & Central America organoids services market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America organoids services market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.